ID 540 - Kwas dokozaheksaenowy, Kwas eikozapentaenowy

PL: Kwas dokozaheksaenowy, Kwas eikozapentaenowy
EN: DHA+EPA - long chain omega 3 fatty acids
Pdf: eicosapentaenoic acid

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituent that is the subject of the health claims is long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFAs), namely docosahexaenoic acid (DHA) in combination with eicosapentaenoic acid (EPA).
The n-3 LCPUFAs, EPA and DHA, are well recognised nutrients and are measurable in foods by established methods. They are well absorbed when consumed in the form of triglycerides. This evaluation applies to EPA and DHA from all sources with appropriate bioavailability in the specified amounts.
The Panel considers that the food constituent, DHA and EPA, which is the subject of the health claims, is sufficiently characterised.

2.1. Rozwój mózgu, oczu i nerwów (ID 501, 513, 540)

The claimed effects are “brain development, cognitive development and cognitive function”, “brain, eye and nerve development and function”, and “support of human neurodevelopment”.
Brain, eye and nerve development is interpreted by the Panel as children's development. The Panel notes that claims related to children's development and health are outside the scope of Article 13 of Regulation (EC) No 1924/2006.

2.2. Utrzymanie prawidłowego funkcjonowania mózgu (ID 497, 501, 510, 513, 519, 521, 534, 540, 688, 1323, 1360, 4294)

The claimed effects are “brain/cognitive function”, “brain development, cognitive development and cognitive function”, “eye, brain and heart health”, “brain, eye and nerve development and function”, “brain and eye function”, “brain function”, “n-3 are essential fatty acids and have critical roles in the membrane structure and as precursors of eicosanoids”, “support of human neurodevelopment”, “eye,
brain and heart health”, “système nerveux, réduction des risques liés au dévelopement de la maladie d'Alzheimer”, “health benefits of food: Dairygold Omega-3 spread contain omega- 3 fatty acids (EPA & DHA) which may have a beneficial role to play in the functioning of the brain and can help maintain a healthy heart”, and “membranes cell structure”. The Panel assumes that the target population is the general population. In the context of the proposed wordings and the clarifications provided, the Panel assumes that the claimed effects refer to the maintenance of normal brain function.
A claim on DHA and maintenance of normal brain function has already been assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010b).

2.3. Utrzymanie prawidłowego wzroku (ID 508, 510, 513, 519, 529, 540, 688, 2905, 4294)

The claimed effects are “eye health”, “eye, brain and heart health”, “brain, eye and nerve development and function”, “brain and eye function”, “support of human neurodevelopment”, “building block for lipids in the retina's photoreceptors; eye health”, and “membranes cell structure”. The Panel assumes that the target population is the general population. In the context of the proposed wordings and the clarifications provided, the Panel assumes that the claimed effects refer to the maintenance of normal vision.
A claim on DHA and maintenance of normal vision has already been assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010b).

Warunki i możliwe ograniczenia stosowania oświadczenia

125 - 500 mg